Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01550003 · ClinicalTrials.gov registry record · Phase 3
Pediatric Arthritis Study of Certolizumab Pegol
A Phase 3 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT01550003: Completed Phase 3 study, sponsored by UCB Biosciences.
NCT01550003 is a Phase 3 study that has completed, run by UCB Biosciences. The registered enrollment target is 193 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01550003, a Phase 3 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Primary Outcome
Certolizumab Pegol (CZP) plasma concentration level was measured in micrograms per milliliter (ug/ml).
Interventions
- DRUG Certolizumab Pegol (CZP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2012-03-08 |
| Est. Completion | 2024-04-08 |
| Phase | Phase 3 |
What the finished NCT01550003 record still lists
NCT01550003 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol (CZP) is the first listed.
NCT01550003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01550003 about?
NCT01550003 is a clinical study titled "Pediatric Arthritis Study of Certolizumab Pegol". A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
What is the current status of trial NCT01550003?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2012-03-08. Estimated completion is 2024-04-08.
What interventions are being tested in trial NCT01550003?
The interventions under investigation include: Certolizumab Pegol (CZP) (DRUG).
Who is sponsoring clinical trial NCT01550003?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01550003's enrollment target sits among peer trials
193 1397th of 2000 higher than 603 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI